These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 31771160)

  • 21. Design of a Broad-Range Bacteriophage Cocktail That Reduces Pseudomonas aeruginosa Biofilms and Treats Acute Infections in Two Animal Models.
    Forti F; Roach DR; Cafora M; Pasini ME; Horner DS; Fiscarelli EV; Rossitto M; Cariani L; Briani F; Debarbieux L; Ghisotti D
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phage ΦPan70, a Putative Temperate Phage, Controls Pseudomonas aeruginosa in Planktonic, Biofilm and Burn Mouse Model Assays.
    Holguín AV; Rangel G; Clavijo V; Prada C; Mantilla M; Gomez MC; Kutter E; Taylor C; Fineran PC; Barrios AF; Vives MJ
    Viruses; 2015 Aug; 7(8):4602-23. PubMed ID: 26274971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phage phiKZ-The First of Giants.
    Krylov V; Bourkaltseva M; Pleteneva E; Shaburova O; Krylov S; Karaulov A; Zhavoronok S; Svitich O; Zverev V
    Viruses; 2021 Jan; 13(2):. PubMed ID: 33498475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pseudomonas aeruginosa bacteriophage PA1Ø requires type IV pili for infection and shows broad bactericidal and biofilm removal activities.
    Kim S; Rahman M; Seol SY; Yoon SS; Kim J
    Appl Environ Microbiol; 2012 Sep; 78(17):6380-5. PubMed ID: 22752161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predation in homogeneous and heterogeneous phage environments affects virulence determinants of Pseudomonas aeruginosa.
    Hosseinidoust Z; Tufenkji N; van de Ven TG
    Appl Environ Microbiol; 2013 May; 79(9):2862-71. PubMed ID: 23435883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. P. aeruginosa flow-cell biofilms are enhanced by repeated phage treatments but can be eradicated by phage-ciprofloxacin combination.
    Henriksen K; Rørbo N; Rybtke ML; Martinet MG; Tolker-Nielsen T; Høiby N; Middelboe M; Ciofu O
    Pathog Dis; 2019 Mar; 77(2):. PubMed ID: 30821815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance against two lytic phage variants attenuates virulence and antibiotic resistance in
    García-Cruz JC; Rebollar-Juarez X; Limones-Martinez A; Santos-Lopez CS; Toya S; Maeda T; Ceapă CD; Blasco L; Tomás M; Díaz-Velásquez CE; Vaca-Paniagua F; Díaz-Guerrero M; Cazares D; Cazares A; Hernández-Durán M; López-Jácome LE; Franco-Cendejas R; Husain FM; Khan A; Arshad M; Morales-Espinosa R; Fernández-Presas AM; Cadet F; Wood TK; García-Contreras R
    Front Cell Infect Microbiol; 2023; 13():1280265. PubMed ID: 38298921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A proposed integrated approach for the preclinical evaluation of phage therapy in Pseudomonas infections.
    Danis-Wlodarczyk K; Vandenheuvel D; Jang HB; Briers Y; Olszak T; Arabski M; Wasik S; Drabik M; Higgins G; Tyrrell J; Harvey BJ; Noben JP; Lavigne R; Drulis-Kawa Z
    Sci Rep; 2016 Jun; 6():28115. PubMed ID: 27301427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of Pseudomonas lytic phages and their application as a cocktail with antibiotics in controlling Pseudomonas aeruginosa.
    Ong SP; Azam AH; Sasahara T; Miyanaga K; Tanji Y
    J Biosci Bioeng; 2020 Jun; 129(6):693-699. PubMed ID: 32107153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Introducing differential RNA-seq mapping to track the early infection phase for
    Wicke L; Ponath F; Coppens L; Gerovac M; Lavigne R; Vogel J
    RNA Biol; 2021 Aug; 18(8):1099-1110. PubMed ID: 33103565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterisation of broad-spectrum phiKZ like jumbo phage and its utilisation in controlling multidrug-resistant Pseudomonas aeruginosa isolates.
    Rai P; Shetty SS; Prabell S; Kuntar A; Pinto D; Kumar BK; Divyashree M; Raj JRM; Premanath R; Deekshit VK; Karunasagar I; Karunasagar I
    Microb Pathog; 2022 Nov; 172():105767. PubMed ID: 36096457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pseudomonas phage inhibition of Candida albicans.
    Nazik H; Joubert LM; Secor PR; Sweere JM; Bollyky PL; Sass G; Cegelski L; Stevens DA
    Microbiology (Reading); 2017 Nov; 163(11):1568-1577. PubMed ID: 28982395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Pseudomonas aeruginosa generalized transducing phage phiPA3 is a new member of the phiKZ-like group of 'jumbo' phages, and infects model laboratory strains and clinical isolates from cystic fibrosis patients.
    Monson R; Foulds I; Foweraker J; Welch M; Salmond GPC
    Microbiology (Reading); 2011 Mar; 157(Pt 3):859-867. PubMed ID: 21163841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spatial structure affects phage efficacy in infecting dual-strain biofilms of
    Testa S; Berger S; Piccardi P; Oechslin F; Resch G; Mitri S
    Commun Biol; 2019; 2():405. PubMed ID: 31701033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phages can constrain protist predation-driven attenuation of Pseudomonas aeruginosa virulence in multienemy communities.
    Friman VP; Buckling A
    ISME J; 2014 Sep; 8(9):1820-30. PubMed ID: 24671085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients.
    Chang RYK; Das T; Manos J; Kutter E; Morales S; Chan HK
    AAPS J; 2019 Apr; 21(3):49. PubMed ID: 30949776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased Innate Immune Susceptibility in Hyperpigmented Bacteriophage-Resistant Mutants of Pseudomonas aeruginosa.
    Menon ND; Penziner S; Montaño ET; Zurich R; Pride DT; Nair BG; Kumar GB; Nizet V
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0023922. PubMed ID: 35862755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of Bacteriophages in Removing Biofilms of
    Fong SA; Drilling A; Morales S; Cornet ME; Woodworth BA; Fokkens WJ; Psaltis AJ; Vreugde S; Wormald PJ
    Front Cell Infect Microbiol; 2017; 7():418. PubMed ID: 29018773
    [No Abstract]   [Full Text] [Related]  

  • 39. Evolution of Antibiotic Resistance in Biofilm and Planktonic Pseudomonas aeruginosa Populations Exposed to Subinhibitory Levels of Ciprofloxacin.
    Ahmed MN; Porse A; Sommer MOA; Høiby N; Ciofu O
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29760140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phages of Pseudomonas aeruginosa: response to environmental factors and in vitro ability to inhibit bacterial growth and biofilm formation.
    Knezevic P; Obreht D; Curcin S; Petrusic M; Aleksic V; Kostanjsek R; Petrovic O
    J Appl Microbiol; 2011 Jul; 111(1):245-54. PubMed ID: 21554503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.